Showing 1271-1280 of 1407 results for "".
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt